Video

Visus CEO updates on lead product candidate, 2021 pipeline

Author(s):

OT Staff Reports
Conferences|AAO

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.


See more AAO coverage here

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
AAO 2024: Weijie Violet Lin, MD, discusses risk factors for epithelium-off cross-linking
Related Content
AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis
November 1st 2024

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

AAO 2024: 3D printed eyeglasses bring vision care to children in underserved, remote communities
October 20th 2024

AAO 2024: 3D printed eyeglasses bring vision care to children in underserved, remote communities

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years
October 20th 2024

AAO 2024: LiGHT trial shows SLT outperforms medications in reducing glaucoma progression over 6 years

© 2024 MJH Life Sciences

All rights reserved.